View ValuationACRO Biomedical 将来の成長Future 基準チェック /06現在、 ACRO Biomedicalの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長29.3%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesNew Risk • Jun 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.7% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (16% increase in shares outstanding). Revenue is less than US$5m (NT$38m revenue, or US$1.2m).New Risk • May 16New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.7% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Revenue is less than US$5m (NT$38m revenue, or US$1.2m).お知らせ • Mar 27ACRO Biomedical Co., Ltd., Annual General Meeting, Jun 29, 2026ACRO Biomedical Co., Ltd., Annual General Meeting, Jun 29, 2026. Location: no,23, lu k`o 5th rd., lujhu district, kaohsiung city TaiwanNew Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 3.1% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Revenue is less than US$5m (NT$37m revenue, or US$1.2m).New Risk • Feb 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 3.1% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Revenue is less than US$5m (NT$37m revenue, or US$1.2m).お知らせ • Apr 14ACRO Biomedical Gains Regulatory Approval for Its Collagen Ophthalmic Matrix, Offering New Hope for Corneal Transplant PatientsACRO Biomedical Co., Ltd. announced that its ABCcolla®? Collagen Ophthalmic Matrix has received regulatory approval from Taiwan'sMinistry of Health and Welfare (MOHW), with registration number: MOHW Medical Device No. 008155. This milestone marks a significant advancement in regenerative medicine and provides new hope for millions awaiting corneal transplants worldwide. According to the World Health Organization (WHO), over 20 million people suffer from blindness due to corneal injuries or infections, yet only around 100,000 corneal transplants are performed annually, leading to a severe shortage. A report from Global Market Insights Inc. estimates the global corneal transplant market to reach $500 million in 2024, with an expected growth to $1 billion by 2033, at a compound annual growth rate (CAGR) of 7.59% from 2025 to 2033. ABCcolla®?Collagen Ophthalmic Matrix is the world's first and only product to utilize supercritical carbon dioxide decellularization technology, ensuring the complete removal of cells and impurities from animal-derived corneal tissue while preserving its intact collagen scaffold. This innovative approach enhances biocompatibility, biodegradability, and tissue regeneration. The product has received patents in 15 countries and won the Silver Award at the 2023 National Pharmaceutical Technology R&D Awards. Notably, there are currently no similar products available in the Taiwanese market. ACRO Biomedical has developed this product using porcine corneas, which closely resemble human corneal structure. Once all cellular components are removed, the material can serve as a biocompatible alternative to donated human corneas, reducing the risk of immune rejection. After rigorous clinical trials, ABCcolla®? Collogen Ophthalmic Matrix has been proven effective for patients suffering from corneal damage caused by melted, trauma, or infections, making it a viable corneal substitute in reconstruction surgeries. The company is preparing for product commercialization to meet market demand and improve patient quality of life. With an aging global population, increasing prevalence of corneal diseases, and rising awareness of vision health, the demand for corneal transplantation and related products is expected to grow steadily. By advancing this breakthrough technology, ACRO Biomedical aims to reduce dependency on donated corneas and restore sight for more patients worldwide. The company remains committed to ongoing innovation in regenerative medicine, striving to become a global leader in the field.Board Change • Apr 04Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. was the last director to join the board, commencing their role in . The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Mar 28ACRO Biomedical Co., Ltd., Annual General Meeting, Jun 26, 2025ACRO Biomedical Co., Ltd., Annual General Meeting, Jun 26, 2025. Location: no,23, lu k`o 5th rd., lujhu district, kaohsiung city TaiwanNew Risk • Mar 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Market cap is less than US$100m (NT$2.17b market cap, or US$65.9m).New Risk • Dec 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (6.1% average weekly change). Market cap is less than US$100m (NT$1.55b market cap, or US$47.5m).New Risk • Apr 30New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (NT$1.61b market cap, or US$49.5m).お知らせ • Apr 04ACRO Biomedical Co., Ltd., Annual General Meeting, Jun 27, 2024ACRO Biomedical Co., Ltd., Annual General Meeting, Jun 27, 2024.New Risk • Feb 19New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 20% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (NT$2.37b market cap, or US$75.5m).New Risk • Aug 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (8.1% average weekly change). Minor Risk Market cap is less than US$100m (NT$2.14b market cap, or US$67.7m).New Risk • Jul 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (6.0% average weekly change). Market cap is less than US$100m (NT$1.65b market cap, or US$53.1m).お知らせ • Apr 10ACRO Biomedical Co., Ltd., Annual General Meeting, Jun 24, 2022ACRO Biomedical Co., Ltd., Annual General Meeting, Jun 24, 2022. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、ACRO Biomedical は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測TPEX:6748 - アナリストの将来予測と過去の財務データ ( )TWD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202538-83-63-49N/A9/30/202537-81-66-49N/A6/30/202537-80-69-50N/A3/31/202540-71-72-47N/A12/31/202444-62-74-43N/A9/30/202450-49-77-45N/A6/30/202456-36-81-47N/A3/31/202454-39-76-48N/A12/31/202351-41-71-48N/A9/30/202341-54-65-48N/A6/30/202331-66-59-47N/A3/31/202329-63-54-46N/A12/31/202228-61-50-45N/A9/30/202226-58-52-47N/A6/30/202224-54-53-49N/A3/31/202223-52-52-48N/A12/31/202122-51-51-48N/A9/30/202122-48-43-39N/A6/30/202122-45-35-31N/A3/31/202120-47-35-31N/A12/31/202018-50-35-31N/A9/30/202014-56-43-40N/A6/30/202010-62-51-48N/A3/31/20209-62-53-48N/A12/31/20197-61-55-49N/A12/31/201817-37N/A-42N/A12/31/20178-50N/A-41N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 6748の予測収益成長が 貯蓄率 ( 1.3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 6748の収益がTW市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 6748の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 6748の収益がTW市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 6748の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 6748の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/04 01:33終値2026/07/03 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋ACRO Biomedical Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Jun 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.7% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (16% increase in shares outstanding). Revenue is less than US$5m (NT$38m revenue, or US$1.2m).
New Risk • May 16New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.7% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Revenue is less than US$5m (NT$38m revenue, or US$1.2m).
お知らせ • Mar 27ACRO Biomedical Co., Ltd., Annual General Meeting, Jun 29, 2026ACRO Biomedical Co., Ltd., Annual General Meeting, Jun 29, 2026. Location: no,23, lu k`o 5th rd., lujhu district, kaohsiung city Taiwan
New Risk • Mar 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 3.1% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Revenue is less than US$5m (NT$37m revenue, or US$1.2m).
New Risk • Feb 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 3.1% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Revenue is less than US$5m (NT$37m revenue, or US$1.2m).
お知らせ • Apr 14ACRO Biomedical Gains Regulatory Approval for Its Collagen Ophthalmic Matrix, Offering New Hope for Corneal Transplant PatientsACRO Biomedical Co., Ltd. announced that its ABCcolla®? Collagen Ophthalmic Matrix has received regulatory approval from Taiwan'sMinistry of Health and Welfare (MOHW), with registration number: MOHW Medical Device No. 008155. This milestone marks a significant advancement in regenerative medicine and provides new hope for millions awaiting corneal transplants worldwide. According to the World Health Organization (WHO), over 20 million people suffer from blindness due to corneal injuries or infections, yet only around 100,000 corneal transplants are performed annually, leading to a severe shortage. A report from Global Market Insights Inc. estimates the global corneal transplant market to reach $500 million in 2024, with an expected growth to $1 billion by 2033, at a compound annual growth rate (CAGR) of 7.59% from 2025 to 2033. ABCcolla®?Collagen Ophthalmic Matrix is the world's first and only product to utilize supercritical carbon dioxide decellularization technology, ensuring the complete removal of cells and impurities from animal-derived corneal tissue while preserving its intact collagen scaffold. This innovative approach enhances biocompatibility, biodegradability, and tissue regeneration. The product has received patents in 15 countries and won the Silver Award at the 2023 National Pharmaceutical Technology R&D Awards. Notably, there are currently no similar products available in the Taiwanese market. ACRO Biomedical has developed this product using porcine corneas, which closely resemble human corneal structure. Once all cellular components are removed, the material can serve as a biocompatible alternative to donated human corneas, reducing the risk of immune rejection. After rigorous clinical trials, ABCcolla®? Collogen Ophthalmic Matrix has been proven effective for patients suffering from corneal damage caused by melted, trauma, or infections, making it a viable corneal substitute in reconstruction surgeries. The company is preparing for product commercialization to meet market demand and improve patient quality of life. With an aging global population, increasing prevalence of corneal diseases, and rising awareness of vision health, the demand for corneal transplantation and related products is expected to grow steadily. By advancing this breakthrough technology, ACRO Biomedical aims to reduce dependency on donated corneas and restore sight for more patients worldwide. The company remains committed to ongoing innovation in regenerative medicine, striving to become a global leader in the field.
Board Change • Apr 04Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. was the last director to join the board, commencing their role in . The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Mar 28ACRO Biomedical Co., Ltd., Annual General Meeting, Jun 26, 2025ACRO Biomedical Co., Ltd., Annual General Meeting, Jun 26, 2025. Location: no,23, lu k`o 5th rd., lujhu district, kaohsiung city Taiwan
New Risk • Mar 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risk Market cap is less than US$100m (NT$2.17b market cap, or US$65.9m).
New Risk • Dec 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (6.1% average weekly change). Market cap is less than US$100m (NT$1.55b market cap, or US$47.5m).
New Risk • Apr 30New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (NT$1.61b market cap, or US$49.5m).
お知らせ • Apr 04ACRO Biomedical Co., Ltd., Annual General Meeting, Jun 27, 2024ACRO Biomedical Co., Ltd., Annual General Meeting, Jun 27, 2024.
New Risk • Feb 19New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 20% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (NT$2.37b market cap, or US$75.5m).
New Risk • Aug 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (8.1% average weekly change). Minor Risk Market cap is less than US$100m (NT$2.14b market cap, or US$67.7m).
New Risk • Jul 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (6.0% average weekly change). Market cap is less than US$100m (NT$1.65b market cap, or US$53.1m).
お知らせ • Apr 10ACRO Biomedical Co., Ltd., Annual General Meeting, Jun 24, 2022ACRO Biomedical Co., Ltd., Annual General Meeting, Jun 24, 2022.